Partial reprogramming gene therapy extends lifespan in mice
A study in mice from the Belmonte group reports about a 12% increase in lifespan with the Cdkn2a-OSK gene therapy, and about 38% more remaining life when it was started at 18 months of age.
Source: Partial reprogramming gene therapy extends lifespan in mice (science.org). Summary written with AI from the source and reviewed by rules; read the original.
What the research shows
The study, carried out by the Belmonte group, tested a gene therapy called Cdkn2a-OSK in mice. According to the report, the therapy increased the animals' lifespan by about 12%. When started at 18 months of age, it was associated with about 38% more remaining lifespan. The evidence comes entirely from animal research, not from people.
Animal studies are a common step in testing anti-aging interventions before any human research. They help scientists observe effects and risks in a living organism, but results in mice do not apply directly to people, since the human body, lifespan and way of delivering a therapy are very different.
What it means
The finding suggests that partial reprogramming of cells may extend lifespan in mice, a result researchers can study in more detail. It is not yet known whether this approach is safe or effective in people, or what its long-term effects would be.
How to read it with care
This result does not replace a medical consultation. Anyone considering any change in diet, supplements or treatment should talk to a doctor or another qualified professional before deciding anything.